Business Wire

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for ...

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now ...
Seeking Alpha

Seres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High Price

Seres Therapeutics launched VOWST for recurrent C. difficile infection in early June, in partnership with Nestle Health. VOWST represents a significant improvement over current standard of care.
Seeking Alpha

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

BRIDGEWATER, N.J., June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which ...
Healio

FDA approves Vowst as first oral microbiota biotherapeutic for recurrent C. difficile

Please provide your email address to receive an email when new articles are posted on . “The availability of a fecal microbiota product that can be taken orally is a significant step forward in ...
Medical Xpress

New treatment for recurrence of C. difficile infection approved by FDA

The U.S. Food and Drug Administration (FDA) has approved VOWST, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for ...
Nasdaq

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) ...
Nasdaq

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in ...

“Since being founded by Flagship Pioneering over a decade ago, Seres has led the development of microbiome therapeutics, and today’s FDA approval of VOWST as the first orally administered ...
Business Wire

Amber Specialty Pharmacy Selected to Dispense VOWST™ Capsules for the Prevention of Recurrence of C. Difficile Infection in Adults

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, an innovator and leader in the specialty pharmacy industry, has been selected as one of only two pharmacies nationally selected by Aimmune ...
Gizmodo

FDA Approves Poop-Based Pill to Treat Hardy Gut Infections

The healing powers of poop can now officially come in a more palatable pill. This week, the Food and Drug Administration approved the drug Vowst, an oral capsule packed with beneficial bacteria ...
Business Insider

Orsini Specialty Pharmacy Now Dispensing VOWST™ (fecal microbiota spores, live - brpk) Capsules for Oral Administration for the Prevention of Recurrence of C. Difficile ...

ELK GROVE VILLAGE, Ill., June 22, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that Aimmune Therapeutics has selected it as a limited distribution partner for VOWST™ (fecal ...
Mena FN

Key Market Driver In Vowst Industry 2025: Rising Prevalence Of Clostridioides Difficile Infections And Their Impact

The Business Research Company's Vowst market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your ...